Cargando…

Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients

SIMPLE SUMMARY: A key point in immunotherapies is to determine tumor cases that are sensitive to immune checkpoint inhibitors (ICI). Effective indicators could accurately evaluate the ICI treatment efficacy. Fatty acid synthase (FASN) is frequently mutated in tumor genomes. In this work, we consolid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qinghua, Tian, Na, Zhang, Wenjing, Lin, Zhijuan, Shi, Fuyan, Kong, Yujia, Ren, Yanfeng, Lyu, Juncheng, Qin, Hao, Liu, Hongqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688165/ https://www.ncbi.nlm.nih.gov/pubmed/36428733 http://dx.doi.org/10.3390/cancers14225638

Ejemplares similares

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
por: Zhang, Wenjing, et al.
Publicado: (2022)

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
por: Zhang, Wenjing, et al.
Publicado: (2022)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma
por: Wang, Qinghua, et al.
Publicado: (2021)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer
por: Li, Zhenpeng, et al.
Publicado: (2022)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Modulation of fatty acid synthase by ATR checkpoint kinase Rad3
por: Qiu, Shuwan, et al.
Publicado: (2019)

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
por: Wang, Qinghua, et al.
Publicado: (2020)

ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas
por: Osella-Abate, Simona, et al.
Publicado: (2018)

Bioinformatic analysis identifies the immunological profile of turner syndrome with different X chromosome origins
por: Qi, Xiao, et al.
Publicado: (2023)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Mutations in Coagulation Factor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma
por: Ping, Zheng, et al.
Publicado: (2017)

Correction: Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
Publicado: (2023)

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma
por: Jiang, Junjie, et al.
Publicado: (2020)

Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival
por: Gao, Yanmei, et al.
Publicado: (2020)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Identification of sucrose synthase from Micractinium conductrix to favor biocatalytic glycosylation
por: Chen, Kai, et al.
Publicado: (2023)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

A family with hypothyroidism caused by fatty acid synthase and apolipoprotein B receptor mutations
por: Sun, Jianhua, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

Identification of fatty acid metabolism–related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma
por: Xu, Yujian, et al.
Publicado: (2022)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
por: Zhang, Wenjing, et al.
Publicado: (2021)

Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
por: Kinget, Lisa, et al.
Publicado: (2021)

Genetic Suppression of Lethal Mutations in Fatty Acid Biosynthesis Mediated by a Secondary Lipid Synthase
por: Allemann, Marco N., et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

High nevus counts confer a favorable prognosis in melanoma patients
por: Ribero, Simone, et al.
Publicado: (2015)

Locally advanced choroidal melanoma with favorable molecular prognosis – case report
por: Bălăşoiu, Andrei-Theodor, et al.
Publicado: (2022)

Fatty Acid Synthase: An Emerging Target in Cancer
por: Fhu, Chee Wai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r1uhtgqqo9ifq67jh82iqtpjdg